Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thiogenesis Therapeutics Corp. has announced progress in its clinical programs for mitochondrial diseases, highlighting its upcoming Phase 2 trial for MELAS in Europe and a planned Phase 2a trial for Leigh Syndrome in partnership with a leading US children’s hospital. These developments underscore the company’s commitment to addressing rare mitochondrial disorders using its novel thiol compounds.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.